Metabolic Profiles Associated With Metformin Efficacy in Cancer

Abstract

Metformin is one of the most commonly prescribed medications for the treatment of type 2 diabetes. Numerous reports have suggested potential anti-cancerous and cancer preventive properties of metformin, although these findings vary depending on the intrinsic properties of the tumor, as well as the systemic physiology of patients. These intriguing studies have led to a renewed interest in metformin use in the oncology setting, and fueled research to unveil its elusive mode of action. It is now appreciated that metformin inhibits complex I of the electron transport chain in mitochondria, causing bioenergetic stress in cancer cells, and rendering them dependent on glycolysis for ATP production. Understanding the mode of action of metformin and the consequences of its use on cancer cell bioenergetics permits the identification of cancer types most susceptible to metformin action. Such knowledge may also shed light on the varying results to metformin usage that have been observed in clinical trials. In this review, we discuss metabolic profiles of cancer cells that are associated with metformin sensitivity, and rationalize combinatorial treatment options. We use the concept of bioenergetic flexibility, which has recently emerged in the field of cancer cell metabolism, to further understand metabolic rearrangements that occur upon metformin treatment. Finally, we advance the notion that metabolic fitness of cancer cells increases during progression to metastatic disease and the emergence of therapeutic resistance. As a result, sophisticated combinatorial approaches that prevent metabolic compensatory mechanisms will be required to effectively manage metastatic disease.

<p>Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend</p>

“…In addition, metformin can act as a cytotoxic agent when cancer cells fail to compensate for this energetic stress, or a cytostatic agent when the cells are able to compensate. 42 …”

The role of an anti-diabetic drug metformin in the treatment of endocrine tumors

“…These patients treated with metformin were characterized by a lower cancer incidence in comparison to patients who were on other anti-diabetic medications (Schulten 2018). Subsequently, several epidemiological data documented the association between metformin therapy and a lower risk of developing breast, colon, pancreatic and liver cancers in diabetic patients (Andrzejewski et al 2018). The realization of the anti-cancer potential of metformin initiated a series of investigations to uncover the role of metformin as a potential drug for the prevention and treatment of a variety of cancers (Vancura et al 2018).…”

Administration of metformin to increase the efficacy of chemotherapy regimen in cancers; a new look to an old drug

“…In proliferating cells like malignancies, this phenomenon may stimulate a cytostatic condition which will reduce the proliferation of cells. In fact, malignant cells in the presence of metformin cannot balance the reduced energy condition, thus cells will go toward apoptosis (12)(13)(14).…”